In addition, clinical trials to test different therapies for patients with HR-positive, HER2-negative breast cancer have focused on clinical response rates as important clinical endpoints (Hurvitz et al., 2020; Johnston et al., 2019; Khan et al., 2020; Whittaker et al., 2017; Ma et al., 2017). The gene discussed is ERBB2; the disease is breast carcinoma.